The Canadian national HPV immunization program was introduced into schools in 2007, 2008, 2009 and 2010 depending on the province. This program is offered to boys and girls (depending on the province and territory) and first vaccination occurs between grades 4 and 8 depending on location. (An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)† Update on Human Papillomavirus (HPV) Vaccines)). 

The vaccines are over 98% effective in preventing cervical abnormalities associated with HPV 16 and 18 in women who have all three doses and in those who have not yet been infected with HPV [1] [2] [3] [4]. However, efficacy is decreased if the vaccinated woman has already contracted the virus. Recent research shows that antibody response to two doses in adolescent girls is as good as a three dose course in the age group. 

More information on the HPV vaccination program: 
http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php

If you are not eligible for the free vaccine you can pay for it privately. Some local pharmacists also offer the vaccine. Talk to your healthcare provider about the HPV vaccine. 

The HPV vaccination will help reduce the number of cases of HPV related cancers and the number of individuals who have to be treated for genital warts or HPV-related cancers. Whether girls/women have been vaccinated or not, the best protection against cervical cancer is to continue going for regular Pap tests and HPV tests for women over 30. The combination of HPV vaccination and cervical screening can help reduce cervical cancer incidence in Canada.

Human papillomavirus immunization programs by province/territory : 

Province/Territory

Routine Schedule for girls- 1,2 and 6 months (Year of implementation)

Routine Schedule for boys (Year of implementation)

Catch-up program for girls 

Catch-up programs for boys 

British Columbia

Grade 6 (2008)

Grade 6 (2017) 

---

 ---

Alberta

Grade 5 (2008)

 Grade 5 (2014)

---

 Grade 9 (from 2014- 2018 only)

Saskatchewan

Grade 6 (2008)

Grade 6 (2017)

---

 ---

Manitoba

Grade 6 (2008)

 Grade 6 (2016)

- Females born between 1997 and 2003 can get up to 3 doses, if they missed the Grade 6 program. 

- Females born between 1986 and 2005 with an increased risk if HPV infection are eligible for the 3 doses, if they started the vaccine series before March 31, 2014. 

- Females who are immunocompromised or HIV-positive and born during or after 1997 are also eligible to receive 3 doses.

 Grades 8+9 (2016)

Ontario

Grade 7 (2007)

Grade 7 (2016)

- Girls starting Grade 8 in the 2016-17 school year will be able to receive the vaccine.

---

Quebec

Grade 4 (2008)

 - Grade 4 (2016)

- Also, men 26 years old and younger, who have sex with other men can get the HPV vaccine free of charge. (2016) 

- 9 to 13 years of age (High Risk of HPV Infections)

- 14-17 years of age

 

- 9 to 17 years of age in First Nations communities

 ---

New Brunswick

Grade 7 (2008)

 Grade 7 (2017) 

---

 ---

Nova Scotia

Grade 7 (2007)

 Grade 7 (2015)

---

 ---

Prince Edward Island

Grade 6 (2007)

 Grade 6 (2013) 

---

 ---

Newfoundland and Labrador

Grade 6 (2007)

 Grade 6 (2017) 

---

 ---

Northwest Territories

Grades 4-6 (2009)

*9-14 yrs: 2 doses

*15 yrs +: 3 doses

 ---

---

 ---

Yukon

Grade 6 (2008-09)

Grade 6 (2017)

---

 ---

Nunavut

Grade 6 (2010)

 ---

 ---

  ---

 

Advisory Committee Statement (ACS) and National Advisory Committee on Immunization (NACI). (2012). Update on Human Papillomavirus (HPV) Vaccines. Canada Communicable Disease Report. Vol. 38


References

  1. Paavonen J. et al., 2009. Efficacy of human papillomavirus (HPV) -16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet, 374 (9686), 301-14.
  2. Szarewski A. 2012. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection againstother high-risk HPV types. Expert Rev. Vaccines 11(6), 645–657.
  3. Dillner J. et al., 2010. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341: c3493. Available online: http://www.bmj.com/content/341/bmj.c3493. Accessed 03.05.2013.
  4. Kjaer S. et al., 2009. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prevention Research 2 (10), 868-878.

"The NHS Vaccination Program." Jo's Cervical Cancer Trust. N.p., 19 Aug. 2013. Web. 02 Mar. 2015.